BioStabilization Systems (BoSS)

Amendment 3:

The purpose of this amendment is to amend the Attachments. Changes to the attachments are listed below:

• Attachment 3 Cost Proposal Narrative: references to "lead organization" were changes to "lead member." See red text on the cover page.
• Attachment 4 Cost Proposal Spreadsheet: On the General tab in the yellow box, under the "Instructions for using this template." See red text on the General tab.

Please carefully review the amended ISO for all changes. 

------------------------------------------------------------------------------------------------------------

Amendment 2:

The purpose of this amendment is to amend the BoSS ISO. An updated version of the ISO, with changes in red font, is included as an attachment to this amendment. 

Changes to the ISO include (but are not limited to):

• clarification of examples of out-of-scope approaches (Table 1)
• update to capability requirements (Section 1.3 Program Overview)
• update to allowable IV&V partner entity types (Section 2)
• update to reporting requirements (Section 3.4 Programmatic Deliverables)

Please carefully review the amended ISO for all changes. 

------------------------------------------------------------------------------------------------------------

Amendment 1 corrects a formatting error on references to Table 2.

------------------------------------------------------------------------------------------------------------

Program Description:

The BioStabilization Systems (BoSS) program aims to transform how live cell-based therapies are stabilized, manufactured, and distributed. At its core, BoSS addresses a foundational bottleneck in the delivery of advanced cell and gene therapies (CGTs): the critical dependence on ultra-cold conditions (-80 to -196˚C) for storage and transport. BoSS will yield a bioprocessing system that enables scalable production of thermally stable cells, paving the way for a new era of efficient and resilient manufacturing and distribution of biologics without any need for cold storage. BoSS-developed technologies will also accelerate many other avenues in biotechnology that directly impact healthcare, including bio-surveillance, regenerative medicine, large-scale genetic testing, blood product supply, and wound repair, in addition to improving access to a wide range of existing biotherapeutics. 

Solution Summaries are required: 

For consideration as a Performer: 

• Solution Summary due date: February 19th, 2026 5:00 PM ET 

For consideration as an IV&V partner:  

• Solution Summary due date: April 17th, 2026 5:00 PM ET 

Interested parties are invited to review the attached BoSS Innovative Solutions Opening (ISO) ARPA-H -SOL-26-136. 

Submissions must be made to:

• Solution Summary Submission Site: https://solutions.arpa-h.gov/Submit-Solution/

Please ensure to follow this opportunity for any updates.

For more information on the BoSS program visit: https://arpa-h.gov/explore-funding/programs/boss.

For information on Proposer's Day details and registration information, please see Special Notice ARPA-H-SN-26-137.